WELLINGTON MANAGEMENT GROUP LLP 13D and 13G filings for Sage Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-06-06 09:54 am Sale | 2024-05-31 | 13G | Sage Therapeutics, Inc. SAGE | WELLINGTON MANAGEMENT GROUP LLP | 39,757 0.070% | -6,022,239 (-99.34%) | Filing |
| 2024-02-08 10:17 am Sale | 2023-12-29 | 13G | Sage Therapeutics, Inc. SAGE | WELLINGTON MANAGEMENT GROUP LLP | 6,061,996 10.100% | -301,634 (-4.74%) | Filing |
| 2023-07-10 08:44 am Purchase | 2023-06-30 | 13G | Sage Therapeutics, Inc. SAGE | WELLINGTON MANAGEMENT GROUP LLP | 6,363,630 10.650% | 847,494 (+15.36%) | Filing |
| 2023-02-06 2:58 pm Sale | 2022-12-30 | 13G | Sage Therapeutics, Inc. SAGE | WELLINGTON MANAGEMENT GROUP LLP | 5,516,136 9.270% | -1,610,275 (-22.60%) | Filing |
| 2022-02-04 09:22 am Purchase | 2021-12-31 | 13G | Sage Therapeutics, Inc. SAGE | WELLINGTON MANAGEMENT GROUP LLP | 7,126,411 12.100% | 999,731 (+16.32%) | Filing |
| 2021-08-10 07:57 am Purchase | 2021-07-30 | 13G | Sage Therapeutics, Inc. SAGE | WELLINGTON MANAGEMENT GROUP LLP | 6,126,680 10.480% | 1,843,051 (+43.03%) | Filing |
| 2021-02-04 10:14 am Purchase | 2020-12-31 | 13G | Sage Therapeutics, Inc. SAGE | WELLINGTON MANAGEMENT GROUP LLP | 4,283,629 8.230% | 4,283,629 (New Position) | Filing |